Tissue sections showing advanced prostate cancer stained with hematoxylin and eosin (left) or an antibody targeting CEACAM5 (right)
Tissue sections showing advanced prostate cancer stained with hematoxylin and eosin (left) or an antibody targeting CEACAM5 (right) Credit: Lee Lab

20202019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012


DeLucia DC, Cardillo TM, Ang LS, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, Gil da Costa RM, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clin Cancer Res. 2020 Nov 16;clincanres.3396.2020. PMID: 33199493.

Diamantopoulos LN, Holt SK, Khaki AR, Sekar RR, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Pstuka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. Clin Genitourin Cancer. 2020 Oct 14;S1558-7673(20)30229-9. PMID: 33160889.

Kwon OJ, Zhang L, Jia D, Zhou Z, Li Z, Haffner M, Lee JK, True L, Morrissey C, Xin L. De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc. Oncogene. 2020 October 2. PMID: 33009488.

VanDeusen HR, Ramroop JR, Morel KL, Bae S, Sheahan AV, Sychev Z, Lau NA, Cheng LC, Tan VM, Li Z, Petersen A, Lee JK, Park JW, Yang R, Hwang JH, Coleman I, Witte ON, Morrissey C, Corey E, Nelson PS, Ellis L, Drake JM. Targeting RET Kinase in Neuroendocrine Prostate Cancer. Mol Cancer Res. 2020 Aug;18(8):1176-1188. PMID: 32461304.

Vichas A, Nkinsi NT, Riley A, Parrish PCR, Duke F, Chen J, Watson J, Rees M, Lee JK, Piccioni F, Hatch E, Berger AH. An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic RIT1 in lung cancer. bioRxiv preprint. 2020 July 3. 

Chour W, Xu AM, Ng AHC, Choi J, Xie J, Yuan D, DeLucia DC, Edmark RA, Jones LC, Schmitt TM, Chaffee ME, Duvvuri VR, Murray KM, Peng S, Wallick J, Algren HA, Berrington WR, O'Mahony DS, Lee JK, Greenberg PD, Goldman JD, Heath JR. Shared Antigen-specific CD8+ T cell Responses Against the SARS-COV-2 Spike Protein in HLA-A*02:01 COIVD-19 Participants. medRxiv preprint. 2020 May 8. 

Corella AN, Victoria Andrea Cabiliza Ordnio M, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown L, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS. Identification of Therapeutic Vulnerabilities in Small Cell Neuroendocrine Prostate Cancer. Clin Cancer Res. 2020 Apr 1;26(7):1667-1677. PMID: 31806643.

DeLucia DC and Lee JK. Identification of Cell Surface Targets for CAR T Cell Immunotherapy. Methods Mol Biol. 2020;2097:45-54. PMID: 31776917.

Diamantopoulos LN, Khaki AR, Grivas P, Gore JL, Schade GR, Hsieh AC, Lee JK, Yezefski T, Yu EY, Schweizer MT, Cheng HH, Psutka SP, Lin DW, Tretiakova MS, Vakar-Lopez F, Montgomery RB, Wright JW. Plasmacytoid bladder cancer variant: response to chemotherapy and oncologic outcomes. Bladder Cancer. 2020 March 28. 


Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flower M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Sci Transl Med. 2019 Dec 4;11(521):eaax0428. PMID: 31801883.

Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019 Dec 1;25(23):6916-6924. PMID: 31363002.

Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman I, Nelson PS, Dehm SM, LeBeau AM. PEG10 promoter-driven expression of reporter genes enables molecular imaging of lethal prostate cancer. Cancer Res. 2019 Nov 1;79(21):5668-5680. PMID: 31530569.

Lee JK and Priceman SJ. Precision Medicine-Enabled Cancer Immunotherapy. Cancer Treat Res. 2019;178:189-205. PMID: 31209846.

Winters BR, De Sarkar N, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight. 2019 May 30;5(13):e128728. PMID: 31145100. 


Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018 Oct 5;362(6410):91-95. PMID: 30287662.

Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482. PMID: 29686080.


Park JW, Lee JK, Witte ON, Huang J. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol. 2017 Sep;30(9):1262-1272. PMID: 28621319.


Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11;29(4):536-547. PMID: 27050099.

Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J, Witte ON. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4482-7. PMID: 27044116.

Drake JM*, Paull EO*, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, Fleming DT, Wong CK, Newton Y, Sudha S, Vashisht AA, Huang J, Wohlschlegel JA, Graeber TG, Witte ON, Stuart JM. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell. 2016 Aug 11;166(4):1041-1054. PMID: 27499020.

Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6457-E6466. PMID: 27694579.


Drake JM, Lee JK, Witte ON. Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer. Mol Cell Biol. 2014 May;34(10):1722-32. PMID: 24567371.


Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):E4762-9. PMID: 24248375.


Lee JK and Schiller G. Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Adv Hematol Oncol. 2012 Jan;10(1):60-2. PMID: 22398811.